Morbo Serpentino
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Sexually Transmitted Disease (STD) Case Definitions (Source: Centers for Disease Control and Prevention
Sexually Transmitted Disease (STD) Case Definitions (Source: Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance, 1997. MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-10).) STD Conditions Reportable in Arizona Chancroid (Revised 9/96) Clinical description A sexually transmitted disease characterized by painful genital ulceration and inflammatory inguinal adenopathy. The disease is caused by infection with Haemophilus ducreyi. Laboratory criteria for diagnosis Isolation of H. ducreyi from a clinical specimen Case classification Probable: a clinically compatible case with both a) no evidence of Treponema pallidum infection by darkfield microscopic examination of ulcer exudate or by a serologic test for syphilis performed ≥7 days after onset of ulcers and b) either a clinical presentation of the ulcer(s) not typical of disease caused by herpes simplex virus (HSV) or a culture negative for HSV. Confirmed: a clinically compatible case that is laboratory confirmed Chlamydia Infection (Revised 6/09) Clinical description Infection with Chlamydia trachomatis may result in urethritis, epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted; however, the infection is often asymptomatic in women. Perinatal infections may result in inclusion conjunctivitis and pneumonia in newborns. Other syndromes caused by C. trachomatis include lymphogranuloma venereum (see Lymphogranuloma Venereum) and trachoma. Laboratory criteria for diagnosis Isolation of C. trachomatis -
Dermatology DDX Deck, 2Nd Edition 65
63. Herpes simplex (cold sores, fever blisters) PREMALIGNANT AND MALIGNANT NON- 64. Varicella (chicken pox) MELANOMA SKIN TUMORS Dermatology DDX Deck, 2nd Edition 65. Herpes zoster (shingles) 126. Basal cell carcinoma 66. Hand, foot, and mouth disease 127. Actinic keratosis TOPICAL THERAPY 128. Squamous cell carcinoma 1. Basic principles of treatment FUNGAL INFECTIONS 129. Bowen disease 2. Topical corticosteroids 67. Candidiasis (moniliasis) 130. Leukoplakia 68. Candidal balanitis 131. Cutaneous T-cell lymphoma ECZEMA 69. Candidiasis (diaper dermatitis) 132. Paget disease of the breast 3. Acute eczematous inflammation 70. Candidiasis of large skin folds (candidal 133. Extramammary Paget disease 4. Rhus dermatitis (poison ivy, poison oak, intertrigo) 134. Cutaneous metastasis poison sumac) 71. Tinea versicolor 5. Subacute eczematous inflammation 72. Tinea of the nails NEVI AND MALIGNANT MELANOMA 6. Chronic eczematous inflammation 73. Angular cheilitis 135. Nevi, melanocytic nevi, moles 7. Lichen simplex chronicus 74. Cutaneous fungal infections (tinea) 136. Atypical mole syndrome (dysplastic nevus 8. Hand eczema 75. Tinea of the foot syndrome) 9. Asteatotic eczema 76. Tinea of the groin 137. Malignant melanoma, lentigo maligna 10. Chapped, fissured feet 77. Tinea of the body 138. Melanoma mimics 11. Allergic contact dermatitis 78. Tinea of the hand 139. Congenital melanocytic nevi 12. Irritant contact dermatitis 79. Tinea incognito 13. Fingertip eczema 80. Tinea of the scalp VASCULAR TUMORS AND MALFORMATIONS 14. Keratolysis exfoliativa 81. Tinea of the beard 140. Hemangiomas of infancy 15. Nummular eczema 141. Vascular malformations 16. Pompholyx EXANTHEMS AND DRUG REACTIONS 142. Cherry angioma 17. Prurigo nodularis 82. Non-specific viral rash 143. Angiokeratoma 18. Stasis dermatitis 83. -
Lepromatous Leprosy with Erythema Nodosum Leprosum Presenting As
Lepromatous Leprosy with Erythema Nodosum Leprosum Presenting as Chronic Ulcers with Vasculitis: A Case Report and Discussion Anny Xiao, DO,* Erin Lowe, DO,** Richard Miller, DO, FAOCD*** *Traditional Rotating Intern, PGY-1, Largo Medical Center, Largo, FL **Dermatology Resident, PGY-2, Largo Medical Center, Largo, FL ***Program Director, Dermatology Residency, Largo Medical Center, Largo, FL Disclosures: None Correspondence: Anny Xiao, DO; Largo Medical Center, Graduate Medical Education, 201 14th St. SW, Largo, FL 33770; 510-684-4190; [email protected] Abstract Leprosy is a rare, chronic, granulomatous infectious disease with cutaneous and neurologic sequelae. It can be a challenging differential diagnosis in dermatology practice due to several overlapping features with rheumatologic disorders. Patients with leprosy can develop reactive states as a result of immune complex-mediated inflammatory processes, leading to the appearance of additional cutaneous lesions that may further complicate the clinical picture. We describe a case of a woman presenting with a long history of a recurrent bullous rash with chronic ulcers, with an evolution of vasculitic diagnoses, who was later determined to have lepromatous leprosy with reactive erythema nodosum leprosum (ENL). Introduction accompanied by an intense bullous purpuric rash on management of sepsis secondary to bacteremia, Leprosy is a slowly progressive disease caused by bilateral arms and face. For these complaints she was with lower-extremity cellulitis as the suspected infection with Mycobacterium leprae (M. leprae). seen in a Complex Medical Dermatology Clinic and source. A skin biopsy was taken from the left thigh, Spread continues at a steady rate in several endemic clinically diagnosed with cutaneous polyarteritis and histopathology showed epidermal ulceration countries, with more than 200,000 new cases nodosa. -
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
2012 Case Definitions Infectious Disease
Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ................................................................................................................................................... -
Diagnostic Issues in Systemic Lupus Erythematosis
266 Postgrad Med J 2001;77:266–285 Postgrad Med J: first published as 10.1136/pmj.77.906.268 on 1 April 2001. Downloaded from SELF ASSESSMENT QUESTIONS Diagnostic issues in systemic lupus erythematosis N Sofat, C Higgens Answers on p 274. A 24 year old woman was diagnosed with sys- (4) What other tests (apart from 24 hour urine temic lupus erythematosis (SLE) based on a creatinine clearance) are available to measure few months’ history of a photosensitive skin the glomerular filtration rate? rash, predominantly on her face, arthralgia The patient had a 24 hour urinary protein col- involving both hands and wrists, a positive lection, which showed a 24 hour protein measure- antinuclear antibody (ANA) test and a raised ment of 1.8 g. There was no evidence of cellular antinative double stranded DNA antibody casts on urine microscopy. Her blood results were binding level. She was treated with oral as below (normal values are in parentheses): hydroxychloroquine 400 mg daily and short x Sodium 134 mmol/l (135–145) courses of prednisolone during flare-ups. x Potassium 4.5 mmol/l (3.5–5.0) She was reviewed in clinic for her regular x Urea 7.0 mmol/l (2.5–6.7) follow up appointment when she was found to x Creatinine 173 µmol/l (70–115) be hypertensive on repeated measurements of x Haemoglobin 108 g/l (115–160) her blood pressure, an average value being x White cell count 4.5 × 109/l (4.0–11.0) 150/90 mm Hg. She was also urine dipstick x Platelets 130 × 109/l (150–400) positive for blood and protein. -
Ear-Nose-Throat Manifestations in Inflammatory Bowel Diseases ANNALS of GASTROENTEROLOGY 2007, 20(4):265-274X Xx 265X
xx xx Ear-nose-throat manifestations in Inflammatory Bowel Diseases ANNALS OF GASTROENTEROLOGY 2007, 20(4):265-274x xx 265x Review Ear-nose-throat manifestations in Inflammatory Bowel Diseases C.D. Zois, K.H. Katsanos, E.V. Tsianos going activation of the innate immune system driven by SUMMARY the presence of luminal flora. Both UC and CD have a Inflammatory bowel diseases (IBD) refer to a group of chron- worldwide distribution and are common causes of mor- ic inflammatory disorders involving the gastrointestinal tract bidity in Western Europe and northern America. and are typically divided into two major disorders: Crohn’s The extraintestinal manifestasions of IBD, however, disease (CD) and ulcerative colitis (UC). CD is characterized are not of less importance. In some cases they are the first by noncontiguous chronic inflammation, often transmural clinical manifestation of the disease and may precede the with noncaseating granuloma formation. It can involve any onset of gastrointestinal symptoms by many years, playing portion of the alimentary tract and CD inflammation has of- also a very important role in disease morbidity. As multi- ten been described in the nose, mouth, larynx and esopha- systemic diseases, IBD, have been correlated with many gus in addition to the more common small bowel and colon other organs, including the skin, eyes, joints, bone, blood, sites. UC differs from CD in that it is characterized by con- kidney, liver and biliary tract. In addition, the inner ear, tiguous chronic inflammation without transmural involve- nose and throat should also be considered as extraintesti- ment, but extraintestinal manifestations of UC have also been nal involvement sites of IBD. -
Erythema Nodosum (En)
Buffalo Medical Group, P.C. Robert E. Kalb, M.D. Phone: (716) 630-1102 Fax: (716) 633-6507 Department of Dermatology 325 Essjay Road Williamsville, New York 14221 ERYTHEMA NODOSUM (EN) Erythema Nodosum (EN) is a relatively uncommon reaction in the skin consisting of red shiny tender nodular lesions most commonly found on the legs. The erythema refers to the red color that is seen at the surface of the skin. The nodosum refers to the fact that these lesions feel like bumps or nodules underneath the skin surface. Erythema nodosum is a reaction pattern occurring in the subcutaneous tissue and fat. It may be preceded by a low grade fever, fatigue, and joint pains. In about half of the cases, there is an internal condition occurring in the body which contributes to its formation. These include the use of certain medications, certain infections, and a number of other less likely causes. In order to identify cause for the erythema nodosum, it may be necessary to perform blood and laboratory tests. At times, however, the cause cannot be determined and erythema nodosum is considered to be idiopathic in nature. Erythema nodosum often runs an acute course lasting for a brief period from weeks to months. In a small percentage of cases, it can be a more chronic condition. The red nodules are usually confined to the lower legs, but can develop anywhere there is fat under the skin including the thighs, arms, and trunk. Initially, the lesions are more red and inflamed in appearance, but with time become more bruise like. -
MYELOPATHY ASSOCIATED with SYSTEMIC LUPUS ERYTHEMATOSUS (Erythema Nodosum)
Paraplegia 16 (1978-79) 282-294 Original Articles MYELOPATHY ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS (Erythema Nodosum) L. S. KEWALRAMANI, M.D., M.S.Orth., S. SALEEM, M.D. and D. BERTRAND, M.T. (ASCP) Texas Institute for Rehabilitation and Research and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, U.S.A. Abstract. Two patients with sudden onset of myelopathy associated with Systemic Lupus Erythematosus (Erythema Nodosum) are described. Pertinent literature is extensively reviewed and these two new patients are added to previously reported 26 patients. Key words: Myelopathy; Meningoencephalomyelopathy; Systemic lupus erythematosus. NEUROLOGICAL manifestations of systemic lupus erythematosus (SLE) have only recently been emphasised although they were mentioned by Kaposi in 1875, who observed stupor and coma as terminal manifestations of the disease. But focal neurological abnormalities were first reported by Osler (1903) and since then there have been several reports in the literature. Most commonly reported entities have been acute organic brain syndrome, seizures and cerebrovascular disorders. Chorea, Guillain Barre syndrome, subarachnoid haemorrhage, peripheral neuro pathy and cranial nerve palsies associated with SLE have also been reported on a few occasions. Myelopathy, however, has not received adequate emphasis as a complication of SLE. Fisher and Gilmour reported the first case of flaccid paraplegia in a female with SLE in 1939. Since then only 25 additional cases have been reported in the medical literature over the past 38 years. Twenty cases have been described in sufficient detail and six briefly, to permit a meaningful review of the spinal cord involvement in this disease. We feel that there are probably many more unreported cases of myelopathy associated with SLE. -
Relapsing Polychondritis
Relapsing polychondritis Author: Professor Alexandros A. Drosos1 Creation Date: November 2001 Update: October 2004 Scientific Editor: Professor Haralampos M. Moutsopoulos 1Department of Internal Medicine, Section of Rheumatology, Medical School, University of Ioannina, 451 10 Ioannina, GREECE. [email protected] Abstract Keywords Disease name and synonyms Diagnostic criteria / Definition Differential diagnosis Prevalence Laboratory findings Prognosis Management Etiology Genetic findings Diagnostic methods Genetic counseling Unresolved questions References Abstract Relapsing polychondritis (RP) is a multisystem inflammatory disease of unknown etiology affecting the cartilage. It is characterized by recurrent episodes of inflammation affecting the cartilaginous structures, resulting in tissue damage and tissue destruction. All types of cartilage may be involved. Chondritis of auricular, nasal, tracheal cartilage predominates in this disease, suggesting response to tissue-specific antigens such as collagen II and cartilage matrix protein (matrillin-1). The patients present with a wide spectrum of clinical symptoms and signs that often raise major diagnostic dilemmas. In about one third of patients, RP is associated with vasculitis and autoimmune rheumatic diseases. The most commonly reported types of vasculitis range from isolated cutaneous leucocytoclastic vasculitis to systemic polyangiitis. Vessels of all sizes may be affected and large-vessel vasculitis is a well-recognized and potentially fatal complication. The second most commonly associated disorder is autoimmune rheumatic diseases mainly rheumatoid arthritis and systemic lupus erythematosus . Other disorders associated with RP are hematological malignant diseases, gastrointestinal disorders, endocrine diseases and others. Relapsing polychondritis is generally a progressive disease. The majority of the patients experience intermittent or fluctuant inflammatory manifestations. In Rochester (Minnesota), the estimated annual incidence rate was 3.5/million. -
Emtree Terms Changed in May 2018
Emtree Terms Changed in May 2021 1 Emtree Terms Added and Changed (May 2021) This is an overview of new terms added and changes made in the second Emtree release in 2021. Overall, Emtree has grown by 1150 preferred terms (140 drug terms and 1010 non-drug terms) compared with the previous version released in January 2021. In total Emtree now counts 90095 preferred terms. Because the terms added include replacements for existing preferred terms (which become synonyms of the new terms) as well as completely new concepts, the number of terms added exceeds the net growth in Emtree. Other changes could include the merging of two or more existing preferred terms into a single concept. The terms added and changed are summarized below and specified in detail on the following pages. Emtree Terms Added in May 2021 1228 new terms (including 78 replacement terms and promoted synonyms) have been added to Emtree as preferred terms in version May 2021 (compared to January 2021): ◼ 179 drug terms (terms assigned to the Chemicals and Drugs facet). ◼ 1049 non-drug terms (terms not assigned as Chemicals and Drugs). The new terms (including the replacement terms and the promoted synonyms) are listed as Terms Added on the following pages. Note that many of these terms will have been indexed prior to 2021 (typically as candidate terms), sometimes for several years, before they were added to Emtree. Emtree Terms Changed in May 2021 78 terms (39 drug terms and 39 non-drug terms) from Emtree January 2020 have been replaced by 76 different terms in May 2021 (39 drug terms and 37 non-drug terms). -
Autoimmune PUK Is Usually Unilateral and Sectoral
1 Q Concerning PUK circumferential Autoimmune PUK is usually unilaterallaterality and sectoralextent . 2 A Concerning PUK Autoimmune PUK is usually unilateral and sectoral 3 Concerning PUK Autoimmune PUK 4 Q Concerning PUK Autoimmune PUK is usually unilateral and sectoral improvement vs It often heralds exacerbationworsening of systemic disease 5 A Concerning PUK Autoimmune PUK is usually unilateral and sectoral It often heralds exacerbation of systemic disease 6 Q Concerning PUK With what general category of autoimmune dz is PUK associated? Autoimmune PUKConnective-tissue is usually dz, unilateral especially vasculitides and sectoral It often heralds exacerbation of systemic disease 7 A Concerning PUK With what general category of autoimmune dz is PUK associated? Autoimmune PUKConnective-tissue is usually dz, unilateral especially vasculitides and sectoral It often heralds exacerbation of systemic disease 8 Q Concerning PUK With what general category of autoimmune dz is PUK associated? Autoimmune PUKConnective-tissue is usually dz, unilateral especially vasculitides and sectoral It often heralds exacerbation of systemic disease With which connective-tissue diseases (CTDs) and/or vasculitides has PUK been associated? Pretty much all of them Which three conditions are most likely to present with PUK? Rheumatoid arthritis, Wegener’s granulomatosis, and polyarteritis nodosa If a PUK pt does not carry a CTD/autoimmune diagnosis, what should the ophthalmologist do? Initiate a diagnostic workup (or promptly arrange for a rheumatologist